Lantern Pharma Unveils AI Drug Development Platform with Zeta.ai
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy LTRN?
Source: Newsfilter
- Investor Briefing: Lantern Pharma will host an investor, analyst, and shareholder briefing on April 9, 2026, showcasing its collaboration with Zeta.ai on a multi-agentic AI platform aimed at addressing critical challenges in rare cancer drug development, which is expected to attract significant attention and boost market confidence.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with rare cancers identified as the most underserved and urgent opportunity, positioning Lantern Pharma's platform to capture a meaningful share through a scalable subscription model, driving future growth.
- Technological Advantage: The multi-agentic architecture of withZeta.ai enables research workflows to simultaneously query multiple knowledge bases, significantly enhancing research efficiency, which is expected to shorten drug development timelines, reduce costs, and accelerate clinical trial processes.
- Business Model: Lantern Pharma will detail its commercial subscription model during the briefing, covering a broad customer base from individual researchers to global pharmaceutical companies, which is anticipated to generate substantial revenue growth and strengthen its position in a competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LTRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LTRN
Wall Street analysts forecast LTRN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.490
Low
25.00
Averages
25.00
High
25.00
Current: 2.490
Low
25.00
Averages
25.00
High
25.00
No data
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lantern Pharma Launches AI Drug Discovery Platform with Subscription Tiers
- Platform Launch: Lantern Pharma announced the commercial launch of its AI-driven drug discovery platform, withZeta.ai, offering introductory, academic, and commercial subscription tiers, creating a new non-dilutive revenue stream for shareholders.
- Nasdaq Market Showcase: On April 16, 2026, Lantern will host an exclusive live demonstration at Nasdaq MarketSite, attracting 25 leading biotech investors and analysts to showcase the platform's real-time multi-database querying and molecule development capabilities, marking a significant milestone in presenting its commercial progress to institutional investors.
- AACR 2026 Debut: Lantern will showcase withZeta.ai at the American Association for Cancer Research Annual Meeting from April 17-22, 2026, attracting global cancer researchers and biopharma executives, demonstrating its application potential in rare cancer drug development, which is expected to expand its commercial subscriber base.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with withZeta.ai positioned as a fully deployed subscription platform aimed at transforming the economics of rare cancer drug development by compressing the costs and time of research and hypothesis generation phases.
See More
Lantern Pharma Unveils AI Drug Development Platform with Zeta.ai
- Investor Briefing: Lantern Pharma will host an investor, analyst, and shareholder briefing on April 9, 2026, showcasing its collaboration with Zeta.ai on a multi-agentic AI platform aimed at addressing critical challenges in rare cancer drug development, which is expected to attract significant attention and boost market confidence.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with rare cancers identified as the most underserved and urgent opportunity, positioning Lantern Pharma's platform to capture a meaningful share through a scalable subscription model, driving future growth.
- Technological Advantage: The multi-agentic architecture of withZeta.ai enables research workflows to simultaneously query multiple knowledge bases, significantly enhancing research efficiency, which is expected to shorten drug development timelines, reduce costs, and accelerate clinical trial processes.
- Business Model: Lantern Pharma will detail its commercial subscription model during the briefing, covering a broad customer base from individual researchers to global pharmaceutical companies, which is anticipated to generate substantial revenue growth and strengthen its position in a competitive market.
See More
Lantern Pharma Q4 2025 Earnings Call Insights
- Significant Clinical Progress: Lantern Pharma achieved clinical validation across multiple programs in 2025, particularly with LP-300 in the Phase II HARMONIC trial, which demonstrated an 86% clinical benefit rate and a 43% objective response rate, indicating potential breakthroughs in cancer treatment.
- Urgent Funding Needs: Management emphasized the necessity to raise substantial additional funding in the near future to support clinical program advancements, with current cash expected to last until late July or mid-September 2026, highlighting operational pressures.
- AI Innovation Commercialization: The company launched the withZeta multi-agentic system aimed at conquering rare cancers and established an AI center of excellence in India, reflecting Lantern Pharma's strategic focus on AI-driven clinical pipelines and commercialization.
- Improved Financial Performance: In Q4 2025, R&D expenses were $2.7 million, significantly down from $4.3 million in the prior year, with a net loss of $4.1 million, demonstrating the company's efforts in cost control and gradual improvement in financial health.
See More
Lantern Pharma Reports Reduced Q4 Net Loss
- Reduced Quarterly Loss: Lantern Pharma reported a net loss of approximately $4.1 million for Q4 2025, a significant decrease from the $5.9 million loss in Q4 2024, indicating progress in cost management efforts.
- Cash Position: As of December 31, 2025, the company held approximately $10.1 million in cash and marketable securities, including about $4.4 million in cash, reflecting a decline in liquidity from $24 million in 2024, raising concerns about future financing needs.
- Operating Expense Decline: Total operating expenses for Q4 2025 were approximately $4.2 million, down from $5.9 million in Q4 2024, showcasing improvements in operational efficiency that could enhance future profitability.
- Financial Health Warning: Despite the reduced losses, cash reserves have decreased significantly from $24 million in 2024 to $10.1 million, indicating potential pressures on the company's ability to sustain operations, necessitating measures to bolster financial stability.
See More
PMGC Holdings Unit Amends Clinical Trial Agreement
- Clinical Trial Agreement Amendment: PMGC Holdings' subsidiary NorthStrive Biosciences amended its deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, targeting muscle and lean mass preservation, which is expected to enhance the company's competitive edge in the biopharmaceutical sector.
- Stock Price Surge: PMGC Holdings' shares soared over 66% in Monday's pre-market trading, despite a 95% year-to-date decline, indicating a positive market reaction to the new clinical trials that may attract investor interest.
- Iterum Therapeutics Winding-Up Petition: Iterum Therapeutics filed a winding-up petition in Ireland, set for hearing on April 13, 2026; although its stock rose 110% in pre-market trading, it remains down 90% year-to-date, reflecting market concerns about its future prospects.
- FDA Approval for New Drug Application: Lantern Pharma's STAR-001 received FDA clearance for clinical trials targeting relapsed or refractory CNS cancers, with shares gaining over 17% in pre-market trading, despite a 63% year-to-date decline, indicating market anticipation for its new therapy.
See More
Leading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
PMGC Holdings Update: PMGC Holdings announced an amended deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, focusing on muscle and lean mass preservation.
Iterum Therapeutics Developments: Iterum Therapeutics filed a winding-up petition in Ireland, set for a hearing on April 13, 2026, while also announcing a significant increase in its stock value.
Lantheus Pharma Progress: Lantheus Pharma received FDA clearance for its new drug application for STAR-001, aimed at treating relapsed or refractory CNS malignancies, and saw a notable rise in its stock.
Market Sentiment: U.S. equities showed positive movement amid ongoing tensions in the Middle East, with retail sentiment regarding the S&P 500 ETF categorized as "extremely bearish."
See More
Lantern Pharma Launches AI Drug Discovery Platform with Subscription Tiers
- Platform Launch: Lantern Pharma announced the commercial launch of its AI-driven drug discovery platform, withZeta.ai, offering introductory, academic, and commercial subscription tiers, creating a new non-dilutive revenue stream for shareholders.
- Nasdaq Market Showcase: On April 16, 2026, Lantern will host an exclusive live demonstration at Nasdaq MarketSite, attracting 25 leading biotech investors and analysts to showcase the platform's real-time multi-database querying and molecule development capabilities, marking a significant milestone in presenting its commercial progress to institutional investors.
- AACR 2026 Debut: Lantern will showcase withZeta.ai at the American Association for Cancer Research Annual Meeting from April 17-22, 2026, attracting global cancer researchers and biopharma executives, demonstrating its application potential in rare cancer drug development, which is expected to expand its commercial subscriber base.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with withZeta.ai positioned as a fully deployed subscription platform aimed at transforming the economics of rare cancer drug development by compressing the costs and time of research and hypothesis generation phases.
See More
Lantern Pharma Unveils AI Drug Development Platform with Zeta.ai
- Investor Briefing: Lantern Pharma will host an investor, analyst, and shareholder briefing on April 9, 2026, showcasing its collaboration with Zeta.ai on a multi-agentic AI platform aimed at addressing critical challenges in rare cancer drug development, which is expected to attract significant attention and boost market confidence.
- Market Opportunity: The global AI drug discovery market is projected to exceed $15 billion by 2030, with rare cancers identified as the most underserved and urgent opportunity, positioning Lantern Pharma's platform to capture a meaningful share through a scalable subscription model, driving future growth.
- Technological Advantage: The multi-agentic architecture of withZeta.ai enables research workflows to simultaneously query multiple knowledge bases, significantly enhancing research efficiency, which is expected to shorten drug development timelines, reduce costs, and accelerate clinical trial processes.
- Business Model: Lantern Pharma will detail its commercial subscription model during the briefing, covering a broad customer base from individual researchers to global pharmaceutical companies, which is anticipated to generate substantial revenue growth and strengthen its position in a competitive market.
See More
Lantern Pharma Q4 2025 Earnings Call Insights
- Significant Clinical Progress: Lantern Pharma achieved clinical validation across multiple programs in 2025, particularly with LP-300 in the Phase II HARMONIC trial, which demonstrated an 86% clinical benefit rate and a 43% objective response rate, indicating potential breakthroughs in cancer treatment.
- Urgent Funding Needs: Management emphasized the necessity to raise substantial additional funding in the near future to support clinical program advancements, with current cash expected to last until late July or mid-September 2026, highlighting operational pressures.
- AI Innovation Commercialization: The company launched the withZeta multi-agentic system aimed at conquering rare cancers and established an AI center of excellence in India, reflecting Lantern Pharma's strategic focus on AI-driven clinical pipelines and commercialization.
- Improved Financial Performance: In Q4 2025, R&D expenses were $2.7 million, significantly down from $4.3 million in the prior year, with a net loss of $4.1 million, demonstrating the company's efforts in cost control and gradual improvement in financial health.
See More
Lantern Pharma Reports Reduced Q4 Net Loss
- Reduced Quarterly Loss: Lantern Pharma reported a net loss of approximately $4.1 million for Q4 2025, a significant decrease from the $5.9 million loss in Q4 2024, indicating progress in cost management efforts.
- Cash Position: As of December 31, 2025, the company held approximately $10.1 million in cash and marketable securities, including about $4.4 million in cash, reflecting a decline in liquidity from $24 million in 2024, raising concerns about future financing needs.
- Operating Expense Decline: Total operating expenses for Q4 2025 were approximately $4.2 million, down from $5.9 million in Q4 2024, showcasing improvements in operational efficiency that could enhance future profitability.
- Financial Health Warning: Despite the reduced losses, cash reserves have decreased significantly from $24 million in 2024 to $10.1 million, indicating potential pressures on the company's ability to sustain operations, necessitating measures to bolster financial stability.
See More
PMGC Holdings Unit Amends Clinical Trial Agreement
- Clinical Trial Agreement Amendment: PMGC Holdings' subsidiary NorthStrive Biosciences amended its deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, targeting muscle and lean mass preservation, which is expected to enhance the company's competitive edge in the biopharmaceutical sector.
- Stock Price Surge: PMGC Holdings' shares soared over 66% in Monday's pre-market trading, despite a 95% year-to-date decline, indicating a positive market reaction to the new clinical trials that may attract investor interest.
- Iterum Therapeutics Winding-Up Petition: Iterum Therapeutics filed a winding-up petition in Ireland, set for hearing on April 13, 2026; although its stock rose 110% in pre-market trading, it remains down 90% year-to-date, reflecting market concerns about its future prospects.
- FDA Approval for New Drug Application: Lantern Pharma's STAR-001 received FDA clearance for clinical trials targeting relapsed or refractory CNS cancers, with shares gaining over 17% in pre-market trading, despite a 63% year-to-date decline, indicating market anticipation for its new therapy.
See More
Leading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
PMGC Holdings Update: PMGC Holdings announced an amended deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, focusing on muscle and lean mass preservation.
Iterum Therapeutics Developments: Iterum Therapeutics filed a winding-up petition in Ireland, set for a hearing on April 13, 2026, while also announcing a significant increase in its stock value.
Lantheus Pharma Progress: Lantheus Pharma received FDA clearance for its new drug application for STAR-001, aimed at treating relapsed or refractory CNS malignancies, and saw a notable rise in its stock.
Market Sentiment: U.S. equities showed positive movement amid ongoing tensions in the Middle East, with retail sentiment regarding the S&P 500 ETF categorized as "extremely bearish."
See More
